Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight).
BACKGROUND
The use of prescription anti-obesity medication (AOM) is becoming increasingly common as treatment options grow and become more accessible. However, AOM may not be without a wide range of potentially negative impacts on patient functioning and well being. The Treatment Related Impact Measure (TRIM-Weight) is an obesity treatment-specific patient reported outcomes (PRO) measure designed to assess the key impacts of prescription anti-obesity medication. This paper will present the validation findings for the TRIM-Weight.


METHODS
The online validation battery survey was administered in four countries (the U.S., U.K., Australia, and Canada). Eligible subjects were over age eighteen, currently taking a prescription AOM and were currently or had been obese during their life. Validation analyses were conducted according to an a priori statistical analysis plan. Item level psychometric and conceptual criteria were used to refine and reduce the preliminary item pool and factor analysis to identify structural domains was performed. Reliability and validity testing was then performed and the minimally importance difference (MID) explored.


RESULTS
Two hundred and eight subjects completed the survey. Twenty-one of the 43 items were dropped and a five-factor structure was achieved: Daily Life, Weight Management, Treatment Burden, Experience of Side Effects, and Psychological Health. A-priori criteria for internal consistency and test-retest coefficients for the total score and all five subscales were met. All pre-specified hypotheses for convergent and known group validity were also met with the exception of the domain of Daily Life (proven in an ad hoc analysis) as well as the 1/2 standard deviation threshold for the MID.


CONCLUSIONS
The development and validation of the TRIM-Weight has been conducted according to well-defined principles for the creation of a PRO measure. Based on the evidence to date, the TRIM-Weight can be considered a brief, conceptually sound, valid and reliable PRO measure.
Brod
Meryl
M
The Brod Group, 219 Julia Avenue, Mill Valley, California 94941, USA. mbrod@thebrodgroup.net
Hammer
Mette
M
Kragh
Nana
N
Lessard
Suzanne
S
Bushnell
Donald M
DM
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011594:Psychometrics; D015203:Reproducibility of Results
D019440:Anti-Obesity Agents